Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy

Grants

Funding Acknowledgements

M. A. S. has sat on advisory boards for and has received research funding from Pfizer, MSD and Gilead Sciences. S. K. has sat on an advisory board for MSD. A. G. has sat on advisory boards for MSD, Gilead and Pfizer. D. C. M. K. has sat on an advisory board for Pfizer and receives financial support (not related to the current work) from Pfizer, MSD and Gilead Sciences. All other authors: none to declare.S.-C. H. is the recipient of an Endeavour Postgraduate Award. We thank Dr Thao Nguyen (Victorian Infectious Diseases Services) and staff from the Health Information Systems of the Royal Melbourne Hospital and the Peter MacCallum Cancer Centre (Melbourne, Australia) for their assistance.